Clinical Trial Identifier: NCT01858532
Trial name: SONAR (Study of Diabetic Nephropathy with Atrasentan)
Diabetes type: Type 2 diabetes.
What it’s testing: The trial is testing a new drug (pill) to prevent diabetic kidney disease called Atrasentan. Atrasentan is an investigational drug that blocks the effects of a peptide called Endothelin-I, which constricts blood vessels in the kidney and causes damage to them.
Why this is new/important: There are no drugs currently available to prevent diabetic kidney disease. This trial hopes to see if Atrasentan can stop disease progression.
What does the trial hope to find? The primary outcome of the study is the onset of end stage renal disease or the doubling of creatinine levels (lower levels are an indication of healthy kidney function). The study will also observe Atrasentan’s effects on heart disease, glomerular filtration rate (or GFR, a test used to check how well the kidneys are working – you can learn more in our learning curve here), and quality of life.
Trial Length: Four years.
Trial Location: 759 locations worldwide, including locations in over 40 states in the US.
- See more at: http://diatribe.org/quest-treat-diabetic-kidn...
Next Discussion: Hi Maize 260 »